Archive: Innovation Radar
Last weekend, akampion went back to the lab for a day to get a first-hand experience of genome editing. In an event organized by Science Bridge e.V. and supported by DFG, Joachim Herz Stiftung and Kassel University, selected participants were able to perform genome editing on an E. coli strain. Read more…
Beyond Sequencing – Agena Bioscience to Present Novel MassArray-based Cancer Diagnostics at ESMO 2016
Visit Agena in Copenhagen to learn how you can combine high sensitivity, accuracy, reliability, and data quality for improved patient management. View customers’ posters, attend Agena´s Investigator Studio presentation, stop by booth #205, or schedule a meeting with Agena directly.
Oral Lecture (Poster)
Routine molecular subgrouping of medulloblastoma: Bridging the divide between research and the clinic using low-cost, mass spectrometry-based DNA methylomics
Friday, October 7th: 17:00 – 17:15
Presenter: Ed Schwalbe, Newcastle University, UK
Clinical Rationale for EGFR T790M Testing in Circulating Tumour DNA
Saturday, October 8th: 16:00 – 16:30
Kiev lecture room
Dr. James Sherwood
Senior Diagnostic Scientist, Personalised Healthcare & Biomarkers, AstraZeneca
Dr. Darryl Irwin
Senior Director, Applications Development, Agena Bioscience
Visit Agena at booth #205
Note: A listing of additional scientific posters available to be viewed at the congress will be available after September 28th.
This week’s Nature publication by researchers of Probiodrug AG and the University of Virginia has received broad coverage in the international media. In Germany and Austria, it made major news in TV (ARD, MDR, ORF) and radio stations (dlf, MDR, dradio), while in the US Rudy Tanzi, neurogeneticist of Harvard Medical School and an advisor on the Alzheimer problem to US-President Barack Obama, was quoted in ScienceNews as saying: “This opens up a whole new view of the disease.”
Alzheimer researcher Thomas Bayer, Professor of Molecular Psychiatry at the University of Goettingen added in MDR INFO that the publication was “a very important contribution”, demonstrating that very small amounts of pGlu Abeta were able to drag normal Abeta peptides along into the deadly cascade and that tau protein was essential for the toxic function.
Angioplasty is the most common medical intervention in the world today – more than 2 million coronary artery patients are treated each year with balloon dilations or stents to widen coronary arteries with the goal to restore normal blood flow to the heart. While the procedure is beneficial in the first place, restenosis is a frequent event in the months after the intervention. It occurs in 10-20% of patients who received coronary artery stents and in up to 50% of patients who had undergone balloon angioplasty. In patients receiving drug-eluting stents (DES), restenosis rate is about 5%. However, these stents in the long run pose the risk of thrombosis. So far, no causal treatment of restenosis is available.
Restenosis is caused by a physiological reaction that is trying to repair the damage induced by the angioplasty procedure. It develops by increased proliferation of vascular smooth muscles cells (VSMCs) in the vessel walls. VSMCs respond to changes in the local environment by adjusting their phenotype from contractile to synthetic, and failure of VSMCs to acquire and maintain the contractile phenotype plays a key role in this process.
Scientists from the Max Planck Institute for Heart and Lung Research have now developed a novel treatment approach. They found that small non-coding RNAs (miRNAs 143/145) specifically expressed in VSMCs control the cells’ phenotypic variation. Therefore, modulation of miRNAs 143/145 levels through activators or stents eluting miRNA 143/145 mimetics may be a very promising approach inhibit restenosis and/or to combat arteriosclerosis.
The technology is being offered by Max-Planck-Innovation.